Tokyo Tape
Sign in
← Medinet

Annual report

2370.TEDINET S100SI7J
Period2022-10-01 → 2023-09-30
Filed2023-12-21
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 83
MetricValuePeriodScopeSource row
Revenue¥662m2022-10-01 → 2023-09-30StandaloneNet sales
Revenue¥634m2021-10-01 → 2022-09-30StandaloneNet sales
Revenue¥683m2020-10-01 → 2021-09-30dStandaloneNet sales (5-year summary)
Revenue¥783m2019-10-01 → 2020-09-30dStandaloneNet sales (5-year summary)
Revenue¥1.1bn2018-10-01 → 2019-09-30dStandaloneNet sales (5-year summary)
Operating income−¥1.4bn2022-10-01 → 2023-09-30StandaloneOperating income
Operating income−¥1.3bn2021-10-01 → 2022-09-30StandaloneOperating income
Ordinary income−¥1.4bn2022-10-01 → 2023-09-30StandaloneOrdinary income
Ordinary income−¥1.3bn2021-10-01 → 2022-09-30StandaloneOrdinary income
Ordinary income−¥871m2020-10-01 → 2021-09-30dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥837m2019-10-01 → 2020-09-30dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥995m2018-10-01 → 2019-09-30dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.4bn2022-10-01 → 2023-09-30StandaloneIncome before income taxes
Profit before tax−¥1.2bn2021-10-01 → 2022-09-30StandaloneIncome before income taxes
Net income−¥1.4bn2022-10-01 → 2023-09-30StandaloneProfit loss
Net income−¥1.3bn2021-10-01 → 2022-09-30StandaloneProfit loss
Net income−¥843m2020-10-01 → 2021-09-30dStandaloneNet income loss (5-year summary)
Net income−¥842m2019-10-01 → 2020-09-30dStandaloneNet income loss (5-year summary)
Net income−¥795m2018-10-01 → 2019-09-30dStandaloneNet income loss (5-year summary)
Total assets¥5.6bnat 2023-09-30StandaloneAssets
Total assets¥6.1bnat 2022-09-30StandaloneAssets
Total assets¥5.4bnat 2021-09-30dStandaloneTotal assets (5-year summary)
Total assets¥5.2bnat 2020-09-30dStandaloneTotal assets (5-year summary)
Total assets¥3.1bnat 2019-09-30dStandaloneTotal assets (5-year summary)
Total liabilities¥590mat 2023-09-30StandaloneLiabilities
Total liabilities¥566mat 2022-09-30StandaloneLiabilities
Net assets / equity¥5.0bnat 2023-09-30StandaloneNet assets
Net assets / equity¥5.5bnat 2022-09-30StandaloneNet assets
Net assets / equity¥4.9bnat 2021-09-30dStandaloneNet assets
Net assets / equity¥4.8bnat 2020-09-30dStandaloneNet assets (5-year summary)
Net assets / equity¥2.6bnat 2019-09-30dStandaloneNet assets (5-year summary)
Cash and deposits¥4.4bnat 2023-09-30StandaloneCash and deposits
Cash and deposits¥4.5bnat 2022-09-30StandaloneCash and deposits
Cash & equivalents¥4.4bnat 2023-09-30StandaloneCash and cash equivalents
Cash & equivalents¥4.5bnat 2022-09-30StandaloneCash and cash equivalents
Cash & equivalents¥4.1bnat 2021-09-30dStandaloneCash and cash equivalents
Cash & equivalents¥3.6bnat 2020-09-30dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥1.4bnat 2019-09-30dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.3bn2022-10-01 → 2023-09-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.2bn2021-10-01 → 2022-09-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥975m2020-10-01 → 2021-09-30dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥633m2019-10-01 → 2020-09-30dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥938m2018-10-01 → 2019-09-30dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow¥3m2022-10-01 → 2023-09-30StandaloneNet cash provided by used in investment activities
Investing cash flow−¥20m2021-10-01 → 2022-09-30StandaloneNet cash provided by used in investment activities
Investing cash flow¥344m2020-10-01 → 2021-09-30dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥86m2019-10-01 → 2020-09-30dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥50m2018-10-01 → 2019-09-30dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥1.2bn2022-10-01 → 2023-09-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.6bn2021-10-01 → 2022-09-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.1bn2020-10-01 → 2021-09-30dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥2.8bn2019-10-01 → 2020-09-30dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥90m2018-10-01 → 2019-09-30dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-6.652022-10-01 → 2023-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-6.332021-10-01 → 2022-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-4.882020-10-01 → 2021-09-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-6.192019-10-01 → 2020-09-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-6.712018-10-01 → 2019-09-30dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥21.64at 2023-09-30StandaloneNet assets per share (5-year summary)
Net assets per share¥26.03at 2022-09-30StandaloneNet assets per share (5-year summary)
Net assets per share¥27.31at 2021-09-30dStandaloneNet assets per share (5-year summary)
Net assets per share¥29.6at 2020-09-30dStandaloneNet assets per share (5-year summary)
Net assets per share¥21.1at 2019-09-30dStandaloneNet assets per share (5-year summary)
Equity ratio89.2%at 2023-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio90.7%at 2022-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio90.8%at 2021-09-30dStandaloneEquity to asset ratio (5-year summary)
Equity ratio90.7%at 2020-09-30dStandaloneEquity to asset ratio (5-year summary)
Equity ratio82.7%at 2019-09-30dStandaloneEquity to asset ratio (5-year summary)
ROE-27.3%2022-10-01 → 2023-09-30StandaloneRate of return on equity (5-year summary)
ROE-24.1%2021-10-01 → 2022-09-30StandaloneRate of return on equity (5-year summary)
ROE-17.5%2020-10-01 → 2021-09-30dStandaloneRate of return on equity (5-year summary)
ROE-23.0%2019-10-01 → 2020-09-30dStandaloneRate of return on equity (5-year summary)
ROE-27.7%2018-10-01 → 2019-09-30dStandaloneRate of return on equity (5-year summary)
Shares issued232,160,757at 2023-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued211,730,423at 2022-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued178,750,423at 2021-09-30dStandaloneTotal number of issued shares (5-year summary)
Shares issued160,830,423at 2020-09-30dStandaloneTotal number of issued shares (5-year summary)
Shares issued120,875,423at 2019-09-30dStandaloneTotal number of issued shares (5-year summary)
Employees98at 2023-09-30StandaloneNumber of employees
Employees96at 2022-09-30StandaloneNumber of employees
Employees83at 2021-09-30dStandaloneNumber of employees
Employees78at 2020-09-30dStandaloneNumber of employees
Employees76at 2019-09-30dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2022-10-01 → 2023-09-30¥6m
Reconciling Itemsreconcilingdepreciation2022-10-01 → 2023-09-30¥19m
Reconciling Itemsreconcilingsegment assetsat 2023-09-30¥4.8bn
Reconciling Itemsreconcilingsegment profit2022-10-01 → 2023-09-30−¥583m
Cellular And Tissue Based Product Businessreportable segmentcapex2022-10-01 → 2023-09-30¥25m
Cellular And Tissue Based Product Businessreportable segmentdepreciation2022-10-01 → 2023-09-30¥28m
Cellular And Tissue Based Product Businessreportable segmentemployeesat 2023-09-3023 pure
Cellular And Tissue Based Product Businessreportable segmentrevenue2022-10-01 → 2023-09-30¥467,000
Cellular And Tissue Based Product Businessreportable segmentrevenue external2022-10-01 → 2023-09-30¥467,000
Cellular And Tissue Based Product Businessreportable segmentsegment assetsat 2023-09-30¥169m
Cellular And Tissue Based Product Businessreportable segmentsegment profit2022-10-01 → 2023-09-30−¥496m
Contracted Cell Manufacturing Businessreportable segmentcapex2022-10-01 → 2023-09-30¥30m
Contracted Cell Manufacturing Businessreportable segmentdepreciation2022-10-01 → 2023-09-30¥55m
Contracted Cell Manufacturing Businessreportable segmentemployeesat 2023-09-3063 pure
Contracted Cell Manufacturing Businessreportable segmentrevenue2022-10-01 → 2023-09-30¥661m
Contracted Cell Manufacturing Businessreportable segmentrevenue external2022-10-01 → 2023-09-30¥661m
Contracted Cell Manufacturing Businessreportable segmentsegment assetsat 2023-09-30¥668m
Contracted Cell Manufacturing Businessreportable segmentsegment profit2022-10-01 → 2023-09-30−¥346m
—segment totalcapex2022-10-01 → 2023-09-30¥55m
—segment totaldepreciation2022-10-01 → 2023-09-30¥84m
—segment totalrevenue2022-10-01 → 2023-09-30¥662m
—segment totalrevenue external2022-10-01 → 2023-09-30¥662m
—segment totalsegment assetsat 2023-09-30¥837m
—segment totalsegment profit2022-10-01 → 2023-09-30−¥842m
Reconciling Itemsreconcilingcapex2021-10-01 → 2022-09-30¥13m
Reconciling Itemsreconcilingdepreciation2021-10-01 → 2022-09-30¥22m
Reconciling Itemsreconcilingsegment assetsat 2022-09-30¥5.3bn
Reconciling Itemsreconcilingsegment profit2021-10-01 → 2022-09-30−¥518m
Cellular And Tissue Based Product Businessreportable segmentcapex2021-10-01 → 2022-09-30¥4m
Cellular And Tissue Based Product Businessreportable segmentdepreciation2021-10-01 → 2022-09-30¥28m
Cellular And Tissue Based Product Businessreportable segmentrevenue2021-10-01 → 2022-09-30¥221,000
Cellular And Tissue Based Product Businessreportable segmentrevenue external2021-10-01 → 2022-09-30¥221,000
Cellular And Tissue Based Product Businessreportable segmentsegment assetsat 2022-09-30¥147m
Cellular And Tissue Based Product Businessreportable segmentsegment profit2021-10-01 → 2022-09-30−¥582m
Contracted Cell Manufacturing Businessreportable segmentcapex2021-10-01 → 2022-09-30¥60m
Contracted Cell Manufacturing Businessreportable segmentdepreciation2021-10-01 → 2022-09-30¥56m
Contracted Cell Manufacturing Businessreportable segmentrevenue2021-10-01 → 2022-09-30¥633m
Contracted Cell Manufacturing Businessreportable segmentrevenue external2021-10-01 → 2022-09-30¥633m
Contracted Cell Manufacturing Businessreportable segmentsegment assetsat 2022-09-30¥643m
Contracted Cell Manufacturing Businessreportable segmentsegment profit2021-10-01 → 2022-09-30−¥233m
—segment totalcapex2021-10-01 → 2022-09-30¥64m
—segment totaldepreciation2021-10-01 → 2022-09-30¥84m
—segment totalrevenue2021-10-01 → 2022-09-30¥634m
—segment totalrevenue external2021-10-01 → 2022-09-30¥634m
—segment totalsegment assetsat 2022-09-30¥790m
—segment totalsegment profit2021-10-01 → 2022-09-30−¥815m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,003
ItemContextValueUnit
Number of shares heldCurrentYearInstant_No9MajorShareholdersMember1005000
Shareholding ratioCurrentYearInstant_No9MajorShareholdersMember0.0043
Number of shares heldCurrentYearInstant_No10MajorShareholdersMember1000000
Shareholding ratioCurrentYearInstant_No10MajorShareholdersMember0.0043
Number of shares heldCurrentYearInstant20511267
Shareholding ratioCurrentYearInstant0.0883
Number of shares issued shares voting rightsCurrentYearInstant_SharesWithNoVotingRightsMember－
Number of shares issued shares voting rightsCurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember－
Number of shares issued shares voting rightsCurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember－
Number of voting rights issued shares voting rightsCurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember－
Number of shares issued shares voting rightsCurrentYearInstant_SharesWithFullVotingRightsTreasurySharesEtcMember－
Number of shares issued shares voting rightsCurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember232136400
Number of voting rights issued shares voting rightsCurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember2321364
Number of shares issued shares voting rightsCurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember24357
Number of shares issued shares voting rightsCurrentYearInstant232160757
Number of voting rights issued shares voting rightsCurrentYearInstant2321364
Number of shares held in own name treasury shares etcCurrentYearInstant_Row1Member－
Number of shares held in others names treasury shares etcCurrentYearInstant_Row1Member－
Total number of shares held treasury shares etcCurrentYearInstant_Row1Member－
Shareholding ratio treasury shares etcCurrentYearInstant_Row1Member－
Number of shares held in own name treasury shares etcCurrentYearInstant－
Number of shares held in others names treasury shares etcCurrentYearInstant－
Total number of shares held treasury shares etcCurrentYearInstant－
Shareholding ratio treasury shares etcCurrentYearInstant－
Number of male directors and other officersFilingDateInstant10
Number of female directors and other officersFilingDateInstant－
Ratio of female directors and other officersFilingDateInstant－
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E05351-000KimuraYoshijiMember7764167
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E05351-000KubushiroKanenaoMember71367
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E05351-000OchiaiMasamiMember108800
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E05351-000KondoTakashigeMember103600
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E05351-000ShinodaTakeshiMember156600
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E05351-000YoshinoKoichiroMember104000
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E05351-000IchikawaKunihideMember10000
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E05351-000TakigamiShinjiMember3000
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E05351-000KatayamaTakuroMember－
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E05351-000HasegawaAkihikoMember－
Number of shares held ordinary shares information about directors and corporate auditorsFilingDateInstant8321534
Audit fees reporting companyPrior1YearDuration18000000JPY
Non audit fees reporting companyPrior1YearDuration－JPY
Audit fees reporting companyCurrentYearDuration17500000JPY
Non audit fees reporting companyCurrentYearDuration－JPY
Total amount of remuneration etc remuneration etc by category of directors and other officersCurrentYearDuration_DirectorsExcludingOutsideDirectorsMember71916000JPY
Fixed remuneration remuneration by category of directors and other officersCurrentYearDuration_DirectorsExcludingOutsideDirectorsMember67250000JPY
Non monetary remuneration remuneration by category of directors and other officersCurrentYearDuration_DirectorsExcludingOutsideDirectorsMember4666000JPY
Number of directors and other officers remuneration etc by category of directors and other officersCurrentYearDuration_DirectorsExcludingOutsideDirectorsMember4
Total amount of remuneration etc remuneration etc by category of directors and other officersCurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember－JPY
Fixed remuneration remuneration by category of directors and other officersCurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember－JPY
Non monetary remuneration remuneration by category of directors and other officersCurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember－JPY
Number of directors and other officers remuneration etc by category of directors and other officersCurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember－

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2022-09-30pass rounding
balance sheet identitynon_consolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2021-09-30pass
statement vs summary · net assetsnon_consolidated 2022-09-30pass
statement vs summary · net assetsnon_consolidated 2023-09-30pass
statement vs summary · operating cash flownon_consolidated 2021-10-01/2022-09-30pass
statement vs summary · operating cash flownon_consolidated 2022-10-01/2023-09-30pass
statement vs summary · revenuenon_consolidated 2021-10-01/2022-09-30pass
statement vs summary · revenuenon_consolidated 2022-10-01/2023-09-30pass
statement vs summary · total assetsnon_consolidated 2022-09-30pass
statement vs summary · total assetsnon_consolidated 2023-09-30pass